Clinical trials: Carcinoma, Hepatocellular
Liver Cancer
A Retrospective Review of Malignant Liver Tumors
This study will review the treatment and outcomes of patients having primary and metastatic hepatic malignancies. Patients treated with surgical resection, percutaneous radiofrequency ablation (RFA), and transarterial…
- Trial name
- NCT00728650
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- University of Oklahoma
Hepatitis B, Chronic (CHB), Hepatitis B
Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
Chronic hepatitis B can develop into cirrhosis and liver cancer, which seriously endangers the life and health of people. In China, HBV is mainly transmitted from mother to child, showing the phenomenon of family clusters.
- Conditions
- Hepatitis B, Chronic (CHB), Hepatitis B, Hepatitis B Virus (HBV)
- Trial name
- NCT07079150
- Testing
- Peg IFN-α-2b
- Where
- 2 sites in China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Advanced Hepatocellular Carcinoma
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of Intravenous CD-801 treatment in subjects with advanced hepatocellular carcinoma(HCC).
- Trial name
- NCT06418659
- Testing
- CD-801
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Changzheng Hospital
Hepatocellular Carcinoma
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
- Trial name
- NCT06961617
- Testing
- LioCyx-M, HBV antigen-specific TCR-redirected T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.
Cirrhosis of Liver
Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Current practice guidelines recommend surveillance for hepatocellular carcinoma (HCC) in liver cirrhosis patients with ultrasonography (USG) every 6 months.
- Trial name
- PRIUS (NCT01446666)
- Where
- South Korea
- Volunteers
- 423 people
- Sponsor
- Asan Medical Center
Liver Cirrhosis, Hepatitis B, Chronic
Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer
HCC surveillance is currently limited by underutilization and the suboptimal performance of AFP. This prospective, single-arm study investigates whether the GAAD score (Gender, Age, AFP, and PIVKA-II) enhances HCC detection when…
- Conditions
- Liver Cirrhosis, Hepatitis B, Chronic, Hepatitis C, Chronic, Carcinoma, Hepatocellular
- Trial name
- STOPHCC-GAAD (NCT07298577)
- Testing
- PIVKA-II and GAAD score calculation
- Where
- Thailand
- Volunteers
- 2,100 people
- Sponsor
- Siriraj Hospital
Hepatocellular Carcinoma, Immune Response
Immunological Response After Ablative Therapy in the Liver
Local ablative treatment of Hepatocellular Carcinoma is performed primary on patients not eligible for liver transplant or liver resection.
- Trial name
- IRAL (NCT03040453)
- Testing
- Microwave ablation, Irreversible electroporation
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Hepatocellular Carcinoma
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Study introduction: this is a multicenter, randomized controlled study of patients with histopathologically confirmed hepatocellular carcinoma (HCC) who have not previously received systematic treatment for HCC, all the patients…
- Trial name
- NCT05056337
- Testing
- Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Carcinoma, Liver Transplant
Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence
This is a retrospective study of single-center cohorts that involves patients with HCC who underwent liver transplantation between January 2016 and 2021, who received livers preserved with Hypothermic Oxygenated Perfusion (HOPE)…
- Conditions
- Liver Carcinoma, Liver Transplant, Tumor Recurrence, Hepato Cellular Carcinoma (HCC)
- Trial name
- NCT06720675
- Testing
- Hypothermic Oxygented Perfusion, Static Cold Storage
- Where
- Italy
- Volunteers
- 237 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Liver Cancer
Chemotherapy in Treating Children With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating children with liver cancer.
- Trial name
- NCT00003912
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma
This study is evaluating the safety and potential effectiveness of adding folic acid to atezolizumab plus bevacizumab as first-line treatment for adults with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07835737
- Testing
- Folic Acid, Atezolizumab & Bevacizumab
- Volunteers
- 78 people
- Sponsor
- West China Hospital
Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
- Trial name
- FAD-HCC-001 (NCT07314372)
- Testing
- Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatocellular Carcinoma.
The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer
Carcinoma is the leading cause of worldwide. Hepatocellular carcinoma (HCC) is the second cause of cancer mortality in Taiwan. Vitamin B-6 and coenzyme Q10 has been recognized as antioxidants and anti-inflammatory nutrients in…
- Trial name
- NCT01964001
- Testing
- Vitamin B-6, Coenzyme Q10, Vitamin B-6+Coenzyme Q10
- Where
- Taiwan
- Volunteers
- 71 people
- Sponsor
- Taichung Veterans General Hospital
Liver Cancer
Vaccine Therapy in Treating Patients With Liver Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
- Trial name
- NCT00005629
- Testing
- AFP gene hepatocellular carcinoma vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- LIVIGNO-2 (NCT06109272)
- Testing
- Livmoniplimab, Budigalimab, Durvalumab
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 89 people
- Sponsor
- AbbVie
Fibrolamellar Hepatocellular Carcinoma
FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with…
- Trial name
- FusionVAC22 (NCT05937295)
- Testing
- Fusion-VAC-XS15
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Primary Hepatocellular Carcinoma
Clinical Study of MAK Immune Cells in the Treatment of PHC
The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral blood mononuclear cells were obtained and then the MAK(Mixed-activated Killer) cells were…
- Trial name
- NCT05242757
- Testing
- Mixed-activated Killer Immune Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhongnan Hospital
Urothelial Carcinoma, Non-Small Cell Lung Cancer
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes…
- Conditions
- Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- IMreal (NCT03782207)
- Testing
- Atezolizumab
- Where
- 257 sites in Argentina, Austria and 28 more
- Volunteers
- 2,756 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC), Real World Study
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
In recent years, immunotherapy represented by PD-1/PD-L1 inhibitors has continuously brought breakthroughs in the treatment of hepatocellular carcinoma and has gradually become the cornerstone of advanced liver cancer treatment.
- Trial name
- NCT07078292
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, HCC
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness…
- Trial name
- NCT01871545
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai